Form 4: Denali Director David Schenkein Receives Equity Awards

Director David P. Schenkein was granted 6,408 restricted stock units and 19,226 stock options as part of annual compensation for his role on the board.

Summary

• David P. Schenkein, a director at Denali Therapeutics, received a grant of 6,408 Restricted Stock Units (RSUs) on June 3, 2026.
• Schenkein also received 19,226 stock options with an exercise price of $19.66 per share.
• Both the RSUs and the stock options are scheduled to vest 100% on the earlier of the one-year anniversary of the grant or the day before the next annual meeting of stockholders.
• Following these transactions, Schenkein directly owns 21,665 shares of common stock, which includes the unvested RSUs.
• Schenkein maintains significant indirect ownership through family trusts, totaling 57,464 shares across two separate revocable trusts.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it confirms the continued engagement of an experienced director and maintains alignment between management and shareholders without indicating any unusual insider selling.

Positives

• Director compensation is heavily weighted toward equity, aligning board interests with those of long-term shareholders.
• The reporting person maintains a substantial total stake in the company, including 26,232 shares in the David P. Schenkein 2004 Revocable Trust and 31,232 shares in the Amy P. Schenkein 2004 Revocable Trust.
• The exercise price of $19.66 for the new options provides a clear benchmark for value creation over the next decade.

Negatives

• The equity grants are dilutive to existing shareholders, though they represent a standard component of director compensation.

Risks

• The value of the granted RSUs and options is entirely dependent on the company's stock price performance and ability to meet clinical or regulatory milestones.
• The options will expire worthless if the stock price does not exceed $19.66 before June 3, 2036.

Future Outlook

The director's equity awards are tied to a one-year vesting schedule, suggesting a commitment to board service through at least the next annual meeting cycle in 2027.

Management Comments

• The reporting person serves as a trustee for the David P. Schenkein 2004 Revocable Trust.
• The reporting person's spouse serves as a trustee for the Amy P. Schenkein 2004 Revocable Trust.

Industry Context

StockSavvy.ai notes that Denali's use of annual equity grants for directors is consistent with industry standards in the biotechnology sector, where companies often use stock-based compensation to attract high-caliber scientific and strategic leadership while preserving cash for research and development.

Comparison to Industry Standards

• The grant size is typical for a mid-cap biotechnology company director.
• The one-year cliff vesting for director awards is a standard corporate governance practice among NASDAQ-listed biotech firms.
• The 10-year option term is the standard duration for incentive and non-qualified stock options in the U.S. market.

Corporate Governance

Related Party Transactions

• Indirect ownership of 26,232 shares through the David P. Schenkein 2004 Revocable Trust.
• Indirect ownership of 31,232 shares through the Amy P. Schenkein 2004 Revocable Trust.

Stakeholder Impact

• Shareholders benefit from the director's continued skin in the game.
• The company preserves cash by using equity for director compensation.

Next Steps

• Vesting of 6,408 RSUs on or before June 3, 2027.
• Vesting of 19,226 stock options on or before June 3, 2027.

Key Dates

Recommendation

The filing details routine insider compensation rather than a strategic shift or unexpected financial result. Investors should maintain their current outlook based on the company's clinical pipeline and broader market conditions.

Keywords

Denali Therapeutics, DNLI, Insider Trading, Form 4, Stock Options, Restricted Stock Units, Director Compensation, Biotechnology, Equity Grant